FR2043504A1 - - Google Patents

Info

Publication number
FR2043504A1
FR2043504A1 FR7015663A FR7015663A FR2043504A1 FR 2043504 A1 FR2043504 A1 FR 2043504A1 FR 7015663 A FR7015663 A FR 7015663A FR 7015663 A FR7015663 A FR 7015663A FR 2043504 A1 FR2043504 A1 FR 2043504A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7015663A
Other languages
French (fr)
Other versions
FR2043504B1 (enExample
Inventor
R E Rodway
R G Simmonds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aspro Nicholas Ltd
Original Assignee
Aspro Nicholas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aspro Nicholas Ltd filed Critical Aspro Nicholas Ltd
Publication of FR2043504A1 publication Critical patent/FR2043504A1/fr
Application granted granted Critical
Publication of FR2043504B1 publication Critical patent/FR2043504B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7015663A 1969-05-03 1970-04-29 Expired FR2043504B1 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB22679/69A GB1293565A (en) 1969-05-03 1969-05-03 Aminophthalazines and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
FR2043504A1 true FR2043504A1 (enExample) 1971-02-19
FR2043504B1 FR2043504B1 (enExample) 1974-10-11

Family

ID=10183355

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7015663A Expired FR2043504B1 (enExample) 1969-05-03 1970-04-29

Country Status (9)

Country Link
US (1) US3753988A (enExample)
JP (1) JPS4839944B1 (enExample)
BE (1) BE749824A (enExample)
CH (1) CH523890A (enExample)
DE (1) DE2021195A1 (enExample)
FR (1) FR2043504B1 (enExample)
GB (1) GB1293565A (enExample)
IE (1) IE33777B1 (enExample)
SE (1) SE376916B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2407927A1 (fr) * 1977-11-03 1979-06-01 Pfizer Nouveaux derives de phtalazine, leur procede de production, et composition pharmaceutique les contenant
WO2004099177A1 (en) * 2003-05-09 2004-11-18 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (enExample) 1977-06-03 1981-03-07 Pfizer
US4370328A (en) 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
DE3575135D1 (de) * 1984-09-14 1990-02-08 Asta Pharma Ag Substituierte benzylphthalazinon-derivate.
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US5106973A (en) * 1987-11-23 1992-04-21 Janssen Pharmaceutica N.V. Pyridzainamine derivatives
US4963676A (en) * 1988-02-09 1990-10-16 Georgia State University Foundation, Inc. Di-substituted phthalazines
JO1645B1 (en) * 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
ES2068413T3 (es) * 1990-03-30 1995-04-16 Mitsubishi Chem Ind Derivados de 4-fenilftalazina.
US5100893A (en) * 1990-04-18 1992-03-31 Janssen Pharmaceutica N.V. Antipicornaviral pyridazinamines
TW279162B (enExample) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US5716956A (en) * 1995-06-07 1998-02-10 Bearsden Bearsden Bio, Inc. Dihydrophthalazine antagonists of excitatory amino acid receptors
CA2275686C (en) 1996-12-18 2006-10-17 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
CO5200835A1 (es) * 1999-09-28 2002-09-27 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
US7977333B2 (en) * 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR028782A1 (es) * 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
SG150534A1 (en) * 2003-11-20 2009-03-30 Janssen Pharmaceutica Nv 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp- ribose) polymerase inhibitors
US7855207B2 (en) 2003-11-20 2010-12-21 Janssen Pharmaceutica, Nv 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adpribose) polymerase inhibitors
UA89618C2 (ru) * 2003-12-05 2010-02-25 Янссен Фармацевтика Н.В. 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы
CA2564996A1 (en) 2004-05-08 2006-01-12 Taeyoung Yoon 3-aryl-5,6-disubstituted pyridazines
WO2005120092A1 (en) * 2004-06-02 2005-12-15 Ktfreetel Co., Ltd. System for providing application and management service and modifying user interface and method thereof
SG154432A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Quinazolinedione derivatives as parp inhibitors
WO2006003147A1 (en) * 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
CA2569826C (en) 2004-06-30 2013-07-16 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
JP2008506716A (ja) * 2004-07-16 2008-03-06 ニトロメッド インコーポレーティッド 心不全に関連する組成物および方法
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
BRPI0613564A2 (pt) 2005-07-04 2011-01-18 Novo Nordisk As compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
BRPI0707223A2 (pt) * 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
CA2634473A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
CA2652135A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
AU2007267197B2 (en) * 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
ES2381446T3 (es) 2007-03-08 2012-05-28 Janssen Pharmaceutica, N.V. Derivado de quinolinona como inhibidores de PARP y TANK
PE20090188A1 (es) * 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2215075B1 (en) * 2007-10-26 2013-12-11 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp inhibitors
AU2009228945B2 (en) * 2008-03-27 2013-05-02 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
HRP20150139T1 (hr) 2008-03-27 2015-05-22 Janssen Pharmaceutica N.V. Tetrahidrofenanthridinoni i tetrahidrociklopentakinolinoni kao inhibitori parp i polimerizacije tubulina
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102202737B (zh) * 2008-11-03 2014-03-26 伊莱利利公司 二取代的2,3-二氮杂萘hedgehog通路拮抗剂
KR101335770B1 (ko) * 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
EP2358698B1 (en) 2008-11-17 2012-09-05 Eli Lilly and Company Tetrasubstituted pyridazine as hedgehog pathway antagonists
US20180093956A1 (en) * 2015-02-06 2018-04-05 Abbvie Inc. Substituted phthalazines
US10947241B2 (en) * 2016-10-28 2021-03-16 Seoul National University Hospital Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US20240174651A1 (en) * 2021-01-28 2024-05-30 The Scripps Research Institute Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022253326A1 (zh) * 2021-06-05 2022-12-08 药捷安康(南京)科技股份有限公司 Nlrp3炎症小体抑制剂及其应用
EP4410787A4 (en) * 2021-09-30 2025-10-15 Origiant Pharmaceutical Co Ltd PHARMACEUTICAL USE AND PROCESS FOR PREPARING A SUBSTITUTED HETEROARYL-PHTHALAZINE DERIVATIVE
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2407927A1 (fr) * 1977-11-03 1979-06-01 Pfizer Nouveaux derives de phtalazine, leur procede de production, et composition pharmaceutique les contenant
WO2004099177A1 (en) * 2003-05-09 2004-11-18 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists
US7329659B2 (en) 2003-05-09 2008-02-12 Merck Sharp & Dohme Limited Substituted-1-phthalazinamines as vr-1 antagonists

Also Published As

Publication number Publication date
BE749824A (fr) 1970-10-30
US3753988A (en) 1973-08-21
IE33777B1 (en) 1974-10-30
DE2021195A1 (de) 1970-11-12
FR2043504B1 (enExample) 1974-10-11
IE33777L (en) 1970-11-03
JPS4839944B1 (enExample) 1973-11-28
SE376916B (enExample) 1975-06-16
GB1293565A (en) 1972-10-18
CH523890A (fr) 1972-06-15

Similar Documents

Publication Publication Date Title
AU2270770A (enExample)
AU465452B2 (enExample)
AU429630B2 (enExample)
AU450150B2 (enExample)
AU442375B2 (enExample)
AU427401B2 (enExample)
AU470301B1 (enExample)
AU442538B2 (enExample)
AU470661B1 (enExample)
AU428131B2 (enExample)
AU425297B2 (enExample)
AU442554B2 (enExample)
AU438128B2 (enExample)
AT308690B (enExample)
AU442285B2 (enExample)
AU442322B2 (enExample)
AU442357B2 (enExample)
AU428074B2 (enExample)
AU442380B2 (enExample)
AU442463B2 (enExample)
AU442535B2 (enExample)
AU410358B2 (enExample)
AU414607B2 (enExample)
AU417208B2 (enExample)
AR203167Q (enExample)

Legal Events

Date Code Title Description
ST Notification of lapse